Cartesian Therapeutics (RNAC) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed Cartesian Therapeutics (RNAC) over the past year, gaining 0.8% versus a loss of 30.4%. Over five years, RNAC leads with a -94.7% price change compared with -97.0% for SABS. SAB Biotherapeutics is the larger company by market cap ($230.2 million vs $189.7 million), about 1.2 times the size, while Cartesian Therapeutics is growing revenue faster (-92.8% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNAC | SABS |
|---|---|---|
| Share price | $6.27 | $2.53 |
| Market cap | $189.70M | $230.20M |
| 1-day change | -4.71% | -2.32% |
| YTD return | -13.04% | -32.35% |
| 1-year return | -30.41% | +0.80% |
| 5-year return | -94.71% | -97.00% |
| EPS (TTM) | $-5.78 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | $0 |
| Revenue growth (YoY) | -92.81% | -100.00% |
| Net income (latest FY) | $-130.30M | $13.27M |
| Operating margin | -5127.10% | — |
| Net margin | -4658.63% | — |
| 52-week high | $11.00 | $5.15 |
| 52-week low | $5.60 | $2.45 |
| Distance from 52-week high | -43.00% | -50.87% |
| Analyst consensus | none | none |
| Avg. price target upside | +437.00% | +360.08% |
| Average volume | 131.23K | 527.29K |
| Shares outstanding | 30.26M | 90.99M |
| Employees | 75 | 86 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SABS has outperformed RNAC by 31.2 percentage points over the past year.
- Cartesian Therapeutics grew revenue faster in its latest fiscal year (-92.81% vs -100.00%).
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Healthcare · Biotechnology · 75 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Healthcare · Biotechnology · 86 employees
RNAC vs SABS FAQ
Which is bigger, Cartesian Therapeutics or SAB Biotherapeutics?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $230.20M compared with $189.70M for Cartesian Therapeutics (RNAC).
Which stock has performed better over the past year, RNAC or SABS?
SABS returned +0.80% over the past 12 months, compared with -30.41% for RNAC (price return, excluding dividends). Past performance does not predict future results.
Are Cartesian Therapeutics and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.